Boston Scientific Corporation
NYSE:BSXMedical - Devices
+$0.45 today
- Market cap
- $63.25B
- Beta
- 0.56
- P/E (TTM)
- 19.0
- EPS (TTM)
- $2.39
Volume 13.21M
Average 19.45M
BSX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Boston Scientific CorporationNYSE: BSX
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $554M rose 5.3% year over year, behind the +17.3% change in trailing-twelve-month research & development. Sequentially, it rose 7.4% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.
Context
- Research & development amounted to 10.2% of revenue in FY2025, up 0.6 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +5.3% toward the trailing-twelve-month pace of +17.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 2.05B USD
- Year-over-year change
- +27.1%
- 4-year CAGR
- +14.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.05B | +27.1% |
| FY2024 | 2024-12-31 | 1.62B | +14.2% |
| FY2023 | 2023-12-31 | 1.41B | +6.9% |
| FY2022 | 2022-12-31 | 1.32B | +9.9% |
| FY2021 | 2021-12-31 | 1.2B | — |
Research & Development vs competitors
How BSX compares with its peers on the latest reported figures
- BSX's LTM Jun 2026 research & development of $2.15B is the 2nd highest of the 11 companies compared; the peer median is $96.6M.
- Its year-over-year change of +17.3% is the 2nd highest of 11, against a peer median of +5.3%.
- Research & development amounts to 10.3% of revenue for BSX, versus a peer median of 8.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $2.92B | +4.9% | +2.1% | 7.8% | |
| LTM Jun 2026 | $2.15B | +17.3% | +15.8% | 10.3% | |
| LTM Jun 2026 | $1.09B | +3.3% | +4.5% | 16.7% | |
| LTM Sep 2026 | $202.57M | +14.5% | +6.0% | 13.4% | |
| LTM Jun 2026 | $195.47M | +23.6% | -2.0% | 7.5% | |
| LTM Sep 2026 | $96.93M | +1.0% | +8.8% | 6.0% | |
| LTM Jun 2026 | $96.27M | -10.6% | +16.3% | 16.9% | |
| LTM Jun 2026 | $92.25M | +1.9% | +4.2% | 6.1% | |
| LTM Mar 2026 | $59.27M | +10.2% | +5.8% | 4.3% | |
| LTM Feb 2026 | $27.86M | +5.7% | -5.2% | 8.9% | |
| LTM Mar 2026 | $11.7M | +10.5% | +3.8% | 19.8% | |
| Peer median (excluding BSX) | $96.6M | +5.3% | +4.3% | 8.3% | |
Competitors are the stored peer set for BSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.89B | 12.68B | 14.24B | 16.75B | 20.07B |
| Cost of Revenue | 4.43B | 4.97B | 5.41B | 6.48B | 6.22B |
| Gross Profit | 7.46B | 7.71B | 8.83B | 10.27B | 13.85B |
| Gross Margin | 62.8% | 60.8% | 62.0% | 61.3% | 69.0% |
| Research & Development | 1.2B | 1.32B | 1.41B | 1.62B | 2.05B |
| Selling, General & Admin | 4.29B | 4.52B | 5.19B | 5.98B | 6.89B |
| Operating Expenses | 5.54B | 5.89B | 6.65B | 7.63B | 9.88B |
| Depreciation & Amortization | 1.09B | 1.14B | 1.2B | 1.27B | 1.37B |
| EBITDA | 2.52B | 2.74B | 3.45B | 3.94B | 5.1B |
| EBITDA Margin | 21.2% | 21.6% | 24.2% | 23.5% | 25.4% |
| Operating Income | 1.92B | 1.82B | 2.18B | 2.64B | 3.97B |
| Operating Margin | 16.2% | 14.4% | 15.3% | 15.7% | 19.8% |
| Interest Income | 4M | 10M | 22M | 107M | 0 |
| Interest Expense | 349M | 464M | 272M | 387M | 349M |
| Other Income / Expenses | (846M) | (683M) | (196M) | (353M) | (586M) |
| Income Before Tax | 1.08B | 1.14B | 1.99B | 2.28B | 3.39B |
| Pre-Tax Margin | 9.1% | 9.0% | 13.9% | 13.6% | 16.9% |
| Income Tax Expense | 36M | 443M | 393M | 436M | 493M |
| Net Income | 1.04B | 698M | 1.59B | 1.85B | 2.89B |
| Net Margin | 8.7% | 5.5% | 11.2% | 11.1% | 14.4% |
| EPS (Basic) | 0.69 | 0.45 | 1.08 | 1.26 | 1.96 |
| EPS (Diluted) | 0.69 | 0.45 | 1.07 | 1.25 | 1.94 |
| Weighted Avg Shares | 1.42B | 1.43B | 1.45B | 1.47B | 1.48B |
| Weighted Avg Shares (Diluted) | 1.43B | 1.44B | 1.46B | 1.49B | 1.49B |
Boston Scientific Corporation
NYSE:BSX
Intrinsic Alpha fair value
Locked
Current Price
$43.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.